此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)

2026年5月21日 更新者:Sheng Li、The Third Peoples Hospital of Dalian

A Prospective, Randomized Controlled, Open-label, Multicenter Clinical Trial of the Efficacy and Safety of Aflibercept Intravitreal Injection (Zhuochuming®) With a 3-month Loading Phase Followed by Treat-and-extend Regimen in Treatment-naïve Patients With Diabetic Macular Edema

The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T&E) can treat patients with diabetic macular edema (DME) who have not received prior treatment. It will also evaluate the safety of Zhuochuming®.

The main questions it aims to answer are:

Can Zhuochuming® using the 3+T&E regimen improve patients' vision better than the traditional pro re nata (3+PRN) regimen?

How much can the macular edema (central retinal thickness) be reduced?

What medical problems (ocular or systemic) will participants experience while taking Zhuochuming®?

What is the difference in the number of injections needed over one year between the two regimens?

Researchers will directly compare Zhuochuming® (3+T&E regimen) with Zhuochuming® (3+PRN regimen) to see which regimen is more effective and convenient for treating DME.

Participants will:

Receive treatment and be followed for 52 weeks (about 1 year)

First receive 3 injections (one every 4 weeks), and then continue according to their assigned group:

T&E group: Injection intervals are gradually extended (up to 16 weeks) based on disease stability

PRN group: Follow-up visits every 4 weeks, with injections given only when needed

Visit the clinic at scheduled times (e.g., before each injection or every 4 weeks) for eye examinations (visual acuity, intraocular pressure, OCT, etc.)

Undergo regular blood tests (complete blood count, liver function, coagulation function, HbA1c, etc.)

Record any discomfort or side effects and report them to the doctor

Study population:

Patients with diabetic macular edema (DME) who have not received prior treatment, aged ≥18 years, and diagnosed with type 1 or type 2 diabetes.

Primary study endpoint:

Change in best-corrected visual acuity (BCVA) from baseline at week 52.

研究概览

研究类型

介入性

注册 (估计的)

186

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Liaoning
      • Dalian、Liaoning、中国、1160033
        • The Third Peoples Hospital of Dalian
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Subject voluntarily participates in the study and signs the informed consent form.
  2. Subject is aged ≥18 years and has a diagnosis of type 1 or type 2 diabetes mellitus.
  3. Refractive status and axial length of the study eye: -6.00D < spherical equivalent < +6.00D, or 21 mm < axial length < 26 mm.
  4. Best-corrected visual acuity (BCVA) of the study eye at screening and baseline is between 78 and 24 ETDRS letters (approximately equivalent to Snellen 20/32 to 20/320).
  5. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose and must use an acceptable method of contraception.
  6. Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study requirements.
  7. The study eye has center-involving diabetic macular edema (DME), defined as central retinal thickness (CRT) ≥300 μm (or ≥320 μm assessed by Heidelberg Spectralis) confirmed by the reading center of the Third People's Hospital of Dalian (primary center) at baseline visit. The reading center is composed of three senior vitreoretinal specialists and experts from the functional examination department of the Third People's Hospital of Dalian.
  8. Visual impairment is primarily caused by DME.

Exclusion Criteria:

  1. Known hypersensitivity to any component of the study drug.
  2. Prior intraocular surgery in the study eye, including macular laser photocoagulation, panretinal photocoagulation, etc.
  3. Prior intraocular or periocular steroid treatment in the study eye.
  4. Prior intravitreal anti-VEGF therapy (e.g., ranibizumab, conbercept, bevacizumab) in the study eye.
  5. Prior photodynamic therapy in the study eye.
  6. Active ocular inflammation (including trace or more) in either eye.
  7. Aphakia or absence of the posterior capsule in the study eye (excluding pseudophakic eyes).
  8. History of corneal transplantation in the study eye.
  9. History of idiopathic or autoimmune uveitis in either eye.
  10. Uncontrolled glaucoma in the study eye (defined as intraocular pressure >25 mmHg despite anti-glaucoma medication) or history of glaucoma filtering surgery.
  11. Any history of vitreous hemorrhage in the study eye within 4 weeks prior to screening.
  12. Presence of other retinal diseases in the study eye, such as retinal detachment, retinal vein occlusion, etc.
  13. Inadequately controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg based on average of ≥2 measurements), allowing improvement with antihypertensive treatment; or history of hypertensive crisis or hypertensive encephalopathy.
  14. Severe cardiovascular disease (myocardial infarction or cerebrovascular accident), unstable arrhythmia, or unstable angina within 3 months prior to the first dose.
  15. Renal failure requiring dialysis or kidney transplantation.
  16. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  17. History of schizophrenia or substance abuse (psychoactive drugs).
  18. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) study or the follow-up phase of an interventional study.
  19. Glycated hemoglobin (HbA1c) level ≥10%, and/or recent signs of uncontrolled diabetes (≥3 episodes of severe hypoglycemia within 3 months before baseline, or hospitalization due to acute hyperglycemia-related complications such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), or other emergencies caused by severe hyperglycemia (e.g., dehydration, electrolyte disturbance, altered consciousness); or ≥2 episodes of DKA within 1 year before baseline, or ≥1 episode of DKA within 3 months before baseline).
  20. Presence of proliferative diabetic retinopathy (PDR) in the study eye.
  21. Ocular disease in the study eye that may confound interpretation of study results, including choroidal neovascularization (CNV) of any cause (e.g., age-related macular degeneration, ocular histoplasmosis, or pathologic myopia).
  22. Cataract in the study eye that causes visual impairment, or patients judged by the investigator as likely to undergo cataract surgery during the study period.
  23. The study eye is aphakic (post-vitrectomy), silicone oil-filled, or gas-filled.
  24. Best-corrected visual acuity (BCVA) of the non-study eye <19 ETDRS letters (approximately equivalent to Snellen 20/400) at screening and baseline.
  25. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:3+T&E Regimen

Experimental:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: treat-and-extend (T&E) regimen. Interval extension (by 2-4 weeks, max 16 weeks) if no intraretinal/subretinal fluid on OCT and no worsening criteria. Interval maintenance if fluid persists but decreases. Interval shortening (by 2-4 weeks, min 6 weeks) if new/recurrent fluid, or BCVA loss ≥5 letters with recurrent fluid, or increase in central retinal thickness ≥100 μm.

Active Comparator:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: pro re nata (PRN) regimen with assessments every 4 weeks. Re-injection criteria: central retinal thickness >250 μm, or increase >50 μm from previous lowest OCT, or loss of ≥5 ETDRS letters in BCVA accompanied by an increase in CRT.

有源比较器:3+PRN Regimen

Experimental:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: treat-and-extend (T&E) regimen. Interval extension (by 2-4 weeks, max 16 weeks) if no intraretinal/subretinal fluid on OCT and no worsening criteria. Interval maintenance if fluid persists but decreases. Interval shortening (by 2-4 weeks, min 6 weeks) if new/recurrent fluid, or BCVA loss ≥5 letters with recurrent fluid, or increase in central retinal thickness ≥100 μm.

Active Comparator:Intravitreal aflibercept 2 mg/0.05 mL (Zhuochuming®), 3 monthly loading doses (W0, W4, W8). From W12: pro re nata (PRN) regimen with assessments every 4 weeks. Re-injection criteria: central retinal thickness >250 μm, or increase >50 μm from previous lowest OCT, or loss of ≥5 ETDRS letters in BCVA accompanied by an increase in CRT.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
To compare the change from baseline in best-corrected visual acuity (BCVA) at week 52 between the experimental group and the control group
大体时间:Week52
Week52

次要结果测量

结果测量
大体时间
Compare the change from baseline in OCT-measured central retinal thickness at week 52 between the experimental and control groups
大体时间:Week 52
Week 52
Compare the proportion of patients achieving a ≥15-letter gain in BCVA from baseline at week 52 between the experimental and control groups
大体时间:Week 52
Week 52
Compare the proportion of patients with a <15-letter loss in BCVA from baseline at week 52 between the experimental and control groups
大体时间:Week 52
Week 52
To compare the number of injections within 52 weeks between the experimental group and the control group
大体时间:Week 52
Week 52
To compare the incidence and severity of adverse events (AE) and serious adverse events (SAE) during the treatment period between the experimental group and the control group
大体时间:From week 0 to week 52, plus a 30-day safety follow-up after the last dose
From week 0 to week 52, plus a 30-day safety follow-up after the last dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月30日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年7月31日

研究注册日期

首次提交

2026年5月21日

首先提交符合 QC 标准的

2026年5月21日

首次发布 (实际的)

2026年5月29日

研究记录更新

最后更新发布 (实际的)

2026年5月29日

上次提交的符合 QC 标准的更新

2026年5月21日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • QL-RE1-25002

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅